Michael Barbella, Managing Editor01.04.23
Lipogems is €12.5 million richer these days, having raised enough growth capital last year (approximately $13.2 million) to support recent U.S. Food and Drug Administration (FDA)-approved IDE studies for a separate and specific indication in knee osteoarthritis (OA).
The current economic size of osteoarthritis therapies is about $7 billion and is expected to reach $16 billion by 2030. Lipogems' minimally invasive procedure is performed one time in a sterile setting (outpatient or operating room) in about 40 minutes and has shown in independent, investigator-initiated studies to improve the pain, function and quality of life of patients with this disabling disease.
ABC Medtech and LIFTT investors are providing Lipogems with the financial resources necessary to:
"In this highly regulated field, Lipogems is the leader in adipose tissue technologies and is currently being utilized in 250-plus U.S. orthopedic centers and military installations, with 60,000 procedures performed to date worldwide," Lipogems President/CEO Carl Llewellyn said. "Of the 125-plus independent peer-reviewed publications supporting Lipogems, over 35 are in knee OA and this FDA study will prove the positive results that are commonly seen in this prevalent and disabling condition. This study and new funding validates our responsible regulatory and commercialization strategy and the trust our shareholder's hold in Lipogems. Our roadmap is geared to provide common debilitating conditions have a simple and effective treatment option."
ABC Company S.p.A. is a permanent capital vehicle publicly listed on Euronext Milan Stock Exchange (ABC). The company's Business Model is structured in the independent areas of Investments and Advisory.
LIFTT is a holding company providing venture capital to early and late-stage ventures in healthcare and other industries. LIFTT was founded and is chaired by entrepreneur and scientist Stefano Buono, founder/CEO of Advanced Accelerator Applications, acquired by Novartis for $3.9 billionn in 2017. Incorporated in 2020, LIFTT is currently invested in 31 companies.
Lipogems is a privately held medical device company that uses adipose tissue solutions to help maintain or restore patient lifestyles and to improve quality of life and recovery times. Lipogems' products are used in a diverse range of areas, including orthopadics, general surgery, plastic and reconstructive surgery, exploring products for wound care, and more. Lipogems products are available in 29 countries.
The current economic size of osteoarthritis therapies is about $7 billion and is expected to reach $16 billion by 2030. Lipogems' minimally invasive procedure is performed one time in a sterile setting (outpatient or operating room) in about 40 minutes and has shown in independent, investigator-initiated studies to improve the pain, function and quality of life of patients with this disabling disease.
ABC Medtech and LIFTT investors are providing Lipogems with the financial resources necessary to:
- Pave the pathway for a knee OA indication and reimbursement in the United States
- Build infrastructure to support growth
- Educate and raise awareness to consumers and patients about knee OA
- Expand into other markets with common conditions that have limited therapeutic options and where microfat can provide life-changing relief
"In this highly regulated field, Lipogems is the leader in adipose tissue technologies and is currently being utilized in 250-plus U.S. orthopedic centers and military installations, with 60,000 procedures performed to date worldwide," Lipogems President/CEO Carl Llewellyn said. "Of the 125-plus independent peer-reviewed publications supporting Lipogems, over 35 are in knee OA and this FDA study will prove the positive results that are commonly seen in this prevalent and disabling condition. This study and new funding validates our responsible regulatory and commercialization strategy and the trust our shareholder's hold in Lipogems. Our roadmap is geared to provide common debilitating conditions have a simple and effective treatment option."
ABC Company S.p.A. is a permanent capital vehicle publicly listed on Euronext Milan Stock Exchange (ABC). The company's Business Model is structured in the independent areas of Investments and Advisory.
LIFTT is a holding company providing venture capital to early and late-stage ventures in healthcare and other industries. LIFTT was founded and is chaired by entrepreneur and scientist Stefano Buono, founder/CEO of Advanced Accelerator Applications, acquired by Novartis for $3.9 billionn in 2017. Incorporated in 2020, LIFTT is currently invested in 31 companies.
Lipogems is a privately held medical device company that uses adipose tissue solutions to help maintain or restore patient lifestyles and to improve quality of life and recovery times. Lipogems' products are used in a diverse range of areas, including orthopadics, general surgery, plastic and reconstructive surgery, exploring products for wound care, and more. Lipogems products are available in 29 countries.